223 related articles for article (PubMed ID: 36203122)
21. Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside.
Ling P; Zheng X; Luo S; Ge J; Xu S; Weng J
Diabetes Obes Metab; 2021 Sep; 23(9):2020-2034. PubMed ID: 34047441
[TBL] [Abstract][Full Text] [Related]
22. Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women.
Persson L; Henriksson P; Westerlund E; Hovatta O; Angelin B; Rudling M
Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):810-4. PubMed ID: 22207727
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors.
Pirillo A; Catapano AL; Norata GD
Curr Atheroscler Rep; 2021 Oct; 23(12):79. PubMed ID: 34698927
[TBL] [Abstract][Full Text] [Related]
24. Effect of long-term physical activity on PCSK9, high- and low-density lipoprotein cholesterol, and lipoprotein(a) levels: a prospective observational trial.
Sponder M; Campean IA; Dalos D; Emich M; Fritzer-Szekeres M; Litschauer B; Bergler-Klein J; Graf S; Strametz-Juranek J
Pol Arch Intern Med; 2017 Aug; 127(7-8):506-511. PubMed ID: 28607329
[TBL] [Abstract][Full Text] [Related]
25. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
[TBL] [Abstract][Full Text] [Related]
26. Relationship between Serum Angiopoietin-like Proteins 3 and 8 and Atherogenic Lipid Biomarkers in Non-Diabetic Adults Depends on Gender and Obesity.
Murawska K; Krintus M; Kuligowska-Prusinska M; Szternel L; Stefanska A; Sypniewska G
Nutrients; 2021 Nov; 13(12):. PubMed ID: 34959891
[TBL] [Abstract][Full Text] [Related]
27. Angiopoietin-Like 3: From Discovery to Therapeutic Gene Editing.
Wang X; Musunuru K
JACC Basic Transl Sci; 2019 Oct; 4(6):755-762. PubMed ID: 31709322
[TBL] [Abstract][Full Text] [Related]
28. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
Reyes-Soffer G; Pavlyha M; Ngai C; Thomas T; Holleran S; Ramakrishnan R; Karmally W; Nandakumar R; Fontanez N; Obunike J; Marcovina SM; Lichtenstein AH; Matthan NR; Matta J; Maroccia M; Becue F; Poitiers F; Swanson B; Cowan L; Sasiela WJ; Surks HK; Ginsberg HN
Circulation; 2017 Jan; 135(4):352-362. PubMed ID: 27986651
[TBL] [Abstract][Full Text] [Related]
29. Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.
Richardson TG; Leyden GM; Wang Q; Bell JA; Elsworth B; Davey Smith G; Holmes MV
PLoS Biol; 2022 Feb; 20(2):e3001547. PubMed ID: 35213538
[TBL] [Abstract][Full Text] [Related]
30. New Trends in Dyslipidemia Treatment.
Jang AY; Lim S; Jo SH; Han SH; Koh KK
Circ J; 2021 May; 85(6):759-768. PubMed ID: 33177309
[TBL] [Abstract][Full Text] [Related]
31. ANGPTL3 serum concentration and rare genetic variants in Finnish population.
Tikka A; Metso J; Jauhiainen M
Scand J Clin Lab Invest; 2017 Dec; 77(8):601-609. PubMed ID: 28972399
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic value of PCSK9 and blood lipid in patients with sepsis].
Chen X; Huang X; Tian H; Kong G; Hu H; Lyu B; Liu X; Lu F; Shang Q; Hao D; Wang X; Wang T
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Jun; 34(6):614-619. PubMed ID: 35924517
[TBL] [Abstract][Full Text] [Related]
33. Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk.
Gobeil É; Bourgault J; Mitchell PL; Houessou U; Gagnon E; Girard A; Paulin A; Manikpurage HD; Côté V; Couture C; Marceau S; Bossé Y; Thériault S; Mathieu P; Vohl MC; Tchernof A; Arsenault BJ
Eur Heart J; 2024 Mar; 45(9):707-721. PubMed ID: 38243829
[TBL] [Abstract][Full Text] [Related]
34. Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects.
Kwakernaak AJ; Lambert G; Muller Kobold AC; Dullaart RP
Thyroid; 2013 Feb; 23(2):166-72. PubMed ID: 23106476
[TBL] [Abstract][Full Text] [Related]
35. ANGPTL3 Deficiency and Risk of Hepatic Steatosis.
D'Erasmo L; Di Martino M; Neufeld T; Fraum TJ; Kang CJ; Burks KH; Di Costanzo A; Minicocci I; Bini S; Maranghi M; Pigna G; Labbadia G; Zheng J; Fierro D; Montali A; Ceci F; Catalano C; Davidson NO; Lucisano G; Nicolucci A; Arca M; Stitziel NO
Circulation; 2023 Nov; 148(19):1479-1489. PubMed ID: 37712257
[TBL] [Abstract][Full Text] [Related]
36. Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism.
Morena M; Le May C; Chenine L; Arnaud L; Dupuy AM; Pichelin M; Leray-Moragues H; Chalabi L; Canaud B; Cristol JP; Cariou B
J Clin Lipidol; 2017; 11(1):87-93. PubMed ID: 28391915
[TBL] [Abstract][Full Text] [Related]
37. Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
Ridker PM; Rifai N; Bradwin G; Rose L
Eur Heart J; 2016 Feb; 37(6):554-60. PubMed ID: 26508163
[TBL] [Abstract][Full Text] [Related]
38. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
[TBL] [Abstract][Full Text] [Related]
39. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
Simonen P; Stenman UH; Gylling H
Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
[TBL] [Abstract][Full Text] [Related]
40. Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients.
Dounousi E; Tellis C; Pavlakou P; Duni A; Liakopoulos V; Mark PB; Papagianni A; Tselepis AD
Oxid Med Cell Longev; 2021; 2021():6677012. PubMed ID: 34336112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
